Research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Genelux in a report released on Monday, March 31st ...

Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Ryvyl (RVYL – Research Report) today. The company’s shares closed yesterday at ...

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Zura Bio (ZURA) to $3 from $5 and keeps a Buy rating on the shares ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy ...

Oculis has significant longer-term potential. However, it remains a high-risk investment given its clinical stage status, and ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

Lifecore Biomedical Inc (LFCR) is expected to report $-0.15 for 3Q. Lindsay Corp (LNN) is expected to report $1.89 for 2Q. MSC Industrial Direct Co - A Share (MSM) is expected to report $0.68 for 2Q.